Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - SAFECODE DRUG TECHNOLOGIES CORP. | Financial_Report.xls |
| EX-31.1 - EXHIBIT 31.1 - SAFECODE DRUG TECHNOLOGIES CORP. | v330411_ex31-1.htm |
| EX-32.2 - EXHIBIT 32.2 - SAFECODE DRUG TECHNOLOGIES CORP. | v330411_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - SAFECODE DRUG TECHNOLOGIES CORP. | v330411_ex31-2.htm |
| 10-Q/A - FORM 10-Q/A - SAFECODE DRUG TECHNOLOGIES CORP. | v330411_10-qa.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
The undersigned, Joel Klopfer, the President and Director (Principal Executive Officer) of SafeCode Drug Technologies Corp. (the “Company”), certifies, under the standards set forth and solely for the purposes of 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge, the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2012 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in that Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: December 17, 2012 | By: | /s/ Joel Klopfer |
| Name Joel Klopfer | ||
| Title: President and Director | ||
| (Principal Executive Officer) |
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.